Modified Frailty Index for Minimally Invasive Distal Pancreatectomy
Evaluation of Postoperative Outcomes of Minimally Invasive Distal Pancreatectomy for Left-sided Pancreatic Tumors Based on the Modified Frailty Index: A Retrospective Cohort Study
1 other identifier
observational
1
1 country
1
Brief Summary
This study aims to investigate the difference in postoperative complications according to the modified Frailty Index (mFI) in patients who underwent minimally invasive distal pancreatectomy for pancreatic tumors at the Asan Medical Center's Department of Hepato-Biliary-Pancreatic Surgery from 2005 to 2019. It also seeks to confirm the utility of mFI as a predictive factor for postoperative complications in frail patients in the future.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Jan 2023
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 10, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
April 10, 2023
CompletedFirst Submitted
Initial submission to the registry
April 19, 2023
CompletedFirst Posted
Study publicly available on registry
May 1, 2023
CompletedMay 1, 2023
April 1, 2023
3 months
April 19, 2023
April 19, 2023
Conditions
Outcome Measures
Primary Outcomes (1)
Postoperative outcomes
Comparison of the Postoperative outcomes according to the mFI
6 months
Study Arms (2)
frail
The mFi categorizes patients with a score of 0.27 or higher as frail and those with a score below that as the non-frail group.
and non-frail
The mFi categorizes patients with a score of 0.27 or higher as frail and those with a score below that as the non-frail group.
Interventions
The mFI includes the following 11 items from the National Surgical Quality Improvement Program (NSQIP): diabetes; functional status (not independent); chronic obstructive pulmonary disease (COPD) or pneumonia; congestive heart failure; history of myocardial infarction; hypertension requiring medication; peripheral vascular disease or rest pain; impaired sensorium; history of either transient ischemic attack or cerebrovascular accident; history of cerebrovascular accident with neurologic deficit; and prior percutaneous coronary intervention, previous coronary surgery, or history of angina.
Eligibility Criteria
This study aims to investigate the trend of frailty among patients who underwent minimally invasive pancreaticoduodenectomy for pancreatic head tumors between January 2005 and December 2019, using data collected until October 31, 2022. Based on an estimated 150 surgeries per year, the sample size is expected to be around 2000 patients. Frailty will be defined as mFI of 0.27 or higher, with an estimated prevalence of 3% among this patient population. The study will analyze the differences and severity of postoperative complications between frail and non-frail patients, while also examining the trend of frailty over the 15-year period. The expected sample size for the study is around 2000 patients.
You may qualify if:
- The study population consists of patients who underwent minimally invasive distal pancreatectomy for pancreatic body or tail tumors between January 2005 and December 2019.
You may not qualify if:
- None
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Song Cheol Kimlead
Study Sites (1)
Asan medical center
Seoul, Republic of Korea, ks013, South Korea
Related Publications (1)
Park Y, Hwang DW, Lee JH, Song KB, Jun E, Lee W, Kwak BJ, Kim SC. Evaluation of postoperative outcomes of minimally invasive distal pancreatectomy for left-sided pancreatic tumors based on the modified frailty index: a retrospective cohort study. Int J Surg. 2023 Nov 1;109(11):3497-3505. doi: 10.1097/JS9.0000000000000670.
PMID: 37598358DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Song Cheol Kim, MD. PhD
Asan Medical Center
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
April 19, 2023
First Posted
May 1, 2023
Study Start
January 1, 2023
Primary Completion
April 10, 2023
Study Completion
April 10, 2023
Last Updated
May 1, 2023
Record last verified: 2023-04
Data Sharing
- IPD Sharing
- Will not share